By Fineline Cube 
China-based Hasten Biopharmaceutical Co., Ltd, backed by CBC Group, announced the completion of Market Authorization Transfers (MAT) for 11 products across multiple Asia-Pacific regions, including Malaysia, Singapore, the Philippines, and Hong Kong, China, during the first half of this year. This milestone marks a significant acceleration in the company’s efforts to build a global commercial ecosystem with Asia-Pacific coverage.
Product Portfolio
The products that have obtained MAT approvals cover therapeutic areas such as cardiovascular diseases and diabetes. Hasten Bio is leveraging its established expertise in regulatory affairs, production transfer, and marketing operations across the Asia-Pacific region.
Strategic Commitment
The company is committed to providing efficient, professional services to help global biopharma partners accelerate their localization and commercialization processes. This facilitates the timely implementation of their Asia-Pacific development strategies.-Fineline Info & Tech